Diana G D, McKinlay M A, Otto M J, Akullian V, Oglesby C
J Med Chem. 1985 Dec;28(12):1906-10. doi: 10.1021/jm00150a025.
A series of [[(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles has been synthesized and evaluated as antipicornavirus agents. The effect of alkyl groups in the 4- and 5-position of the oxazoline ring, as well as the alkyl chain length, on antiviral activity was examined. Compound 14 was evaluated in vivo and was found to significantly reduce mortality at an oral dose of 4 mg/kg in mice infected intracerebrally with poliovirus-2. Compound 14 was also effective in preventing paralysis when administered intraperitoneally to mice infected subcutaneously with a lethal dose of ECHO-9 virus. On the basis of the results of these studies, compound 14 is a strong candidate for clinical evaluation as a systemic agent for the treatment of picornavirus infections.
已合成了一系列[[(4,5-二氢-2-恶唑基)苯氧基]烷基]异恶唑并作为抗微小核糖核酸病毒剂进行了评估。研究了恶唑啉环4位和5位的烷基以及烷基链长度对抗病毒活性的影响。化合物14进行了体内评估,发现在以4mg/kg口服剂量给予脑内感染脊髓灰质炎病毒2型的小鼠时,可显著降低死亡率。当以腹腔注射方式给予皮下感染致死剂量埃可病毒9型的小鼠时,化合物14在预防麻痹方面也有效。基于这些研究结果,化合物14作为治疗微小核糖核酸病毒感染的全身用药进行临床评估的强有力候选药物。